MBRX
Moleculin Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.77
−0.88%Sep 18, 2026, 21:07 UTC
Moleculin Biotech, Inc. received a Nasdaq notice dated September 15, 2026 for failing to comply with the minimum bid price requirement under Rule 5550(a)(2) and intends to request a hearing before the Nasdaq Hearings Panel.
Sep 14, 2026, 12:35 UTC
Moleculin announced it will present new Annamycin data at the AACR Conference on Pancreatic Cancer and two European scientific meetings.
Source:Aug 14, 2026, 12:30 UTC
Moleculin Biotech reported financial results for the second quarter ended June 30, 2026, and highlighted progress in its pivotal MIRACLE trial for Annamycin in relapsed/refractory AML.
Source:Jul 31, 2026, 14:12 UTC
Moleculin Biotech priced a best-efforts public offering of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 37,130,001 shares at a combined price of $0.75 per share, expected to close on or about August 3, 2026.
Source:Jul 31, 2026, 12:10 UTC
Moleculin Biotech reported positive interim data from its MIRACLE R/R AML trial, showing a blinded CRc of 37% in venetoclax-failed patients, with enrollment at 74 of 90 patients and final Part A treatment expected in September 2026.
Jun 30, 2026, 12:30 UTC
Moleculin Biotech announced positive interim results from its Phase 2/3 MIRACLE trial for Annamycin in relapsed or refractory acute myeloid leukemia.